JN

Jeffrey Nau

Chief Executive Officer

Aviceda Therapeutics

Pennington, New Jersey


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Aviceda Therapeutics
Industry
research
Employees
34.0
Seniority
C suite
Annual Revenue
3111000.0
Total Funding
252358553.0
Latest Funding
Series C

Technologies

Outlook Amazon AWS Netlify BambooHR Mobile Friendly Remote AI

Keywords

biotechnology research glyco-immune therapeutics immune modulation avd-104 geographic atrophy macular degeneration sialic acid mimetics nanoparticle delivery high affinity ligands immune checkpoint inhibitors chronic inflammation macrophage repolarization immune response targeting innate immune system clinical trials ophthalmology retinal diseases diabetic macular edema diabetic retinopathy complement system biodegradable nanoparticles therapeutic nanoparticles sialic acid-coated nanoparticles drug development novel therapies retinal therapeutics cancer therapies fibrosis treatment neurological disorders neuroinflammation cns injury treatment biotech innovation cell signaling pathways biologic therapeutics personalized medicine precision therapy chronic disease management therapeutic applications biotechnology ocular diseases pharmaceutical research therapeutic efficacy safety profile clinical efficacy pharmacokinetics immune cell engagement high-throughput screening immunology drug targets age-related macular degeneration biopharma health care health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans